to which patients complied with these orders. Making more referrals to pulmonary rehabilitation and smoking cessation programs, and recommending new inhaler regimens, have the potential to improve outcomes, but only if patients adhere to these recommendations. Third, a curious finding was that similar clinical benefits were observed regardless of whether patients were considered to have COPD, raising questions about the mechanism of action of the intervention.

Beyond the results presented in this manuscript, the study raises as many questions as it answers, begging further investigation. For example, qualitative methods could be used to assess the perspective of PCP and health system administrators to better understand acceptability, feasibility, and sustainability to strengthen the intervention for future applications. Second, the application of implementation frameworks might generate additional insights regarding how and why the program succeeded and failed (11). Theoretical frameworks can "enable knowledge to emerge out of seeming chaos and for translation of that knowledge to be widely and reliably implemented" (12).

Ultimately, the most significant aspect of this trial was that it yielded clinical benefits without burdening busy PCPs with a cascade of "best practice alerts" and other forms of workflow interruption. Surveillance, hovering, and proactive e-consultation like those tested here are population health management techniques that have shown promise in other settings and may represent a path toward better outcomes for patients with COPD and other chronic conditions (13). We look forward to future research aimed at evaluating the costs and benefits of such approaches.

<u>Author disclosures</u> are available with the text of this article at www.atsjournals.org.

Peter K. Lindenauer, M.D., M.Sc. Department of Healthcare Delivery and Population Sciences University of Massachusetts Chan Medical School – Baystate Springfield, Massachusetts

Mark V. Williams, M.D. Department of Medicine Washington University School of Medicine St. Louis, Missouri

References

- Ford ES. Hospital discharges, readmissions, and ED visits for COPD or bronchiectasis among US adults: findings from the nationwide inpatient sample 2001-2012 and Nationwide Emergency Department sample 2006-2011. Chest 2015;147:989–998.
- Lindenauer PK, Dharmarajan K, Qin L, Lin Z, Gershon AS, Krumholz HM. Risk trajectories of readmission and death in the first year after hospitalization for chronic obstructive pulmonary disease. Am J Respir Crit Care Med.
- Prieto-Centurion V, Markos MA, Ramey NI, Gussin HA, Nyenhuis SM, Joo MJ, et al. Interventions to reduce rehospitalizations after chronic obstructive pulmonary disease exacerbations. A systematic review. Ann Am Thorac Soc 2014;11:417–424.
- Press VG, Myers LC, Feemster LC. Preventing COPD readmissions under the Hospital Readmissions Reduction Program: how far have we come? Chest 2021;159:996–1006.
- Fan VS, Gaziano JM, Lew R, Bourbeau J, Adams SG, Leatherman S, et al. A comprehensive care management program to prevent chronic obstructive pulmonary disease hospitalizations: a randomized, controlled trial. Ann Intern Med 2012;156:673–683.
- Aboumatar H, Naqibuddin M, Chung S, Chaudhry H, Kim SW, Saunders J, et al. Effect of a hospital-initiated program combining transitional care and long-term self-management support on outcomes of patients hospitalized with chronic obstructive pulmonary disease: a randomized clinical trial. JAMA 2019;322:1371–1380.
- Benzo R, Vickers K, Novotny PJ, Tucker S, Hoult J, Neuenfeldt P, et al. Health coaching and chronic obstructive pulmonary disease rehospitalization. A randomized study. Am J Respir Crit Care Med 2016; 194:672–680.
- Ryrsø CK, Godtfredsen NS, Kofod LM, Lavesen M, Mogensen L, Tobberup R, et al. Lower mortality after early supervised pulmonary rehabilitation following COPD-exacerbations: a systematic review and meta-analysis. BMC Pulm Med 2018;18:154.
- Au DH, Collins MP, Berger DB, Carvalho PG, Nelson KM, Reinke LF, et al. Health system approach to improve chronic obstructive pulmonary disease care after hospital discharge: stepped-wedge clinical trial. Am J Respir Crit Care Med 2022;205:1281–1289.
- 10. van Dam van Isselt EF, Spruit M, Groenewegen-Sipkema KH, Chavannes NH, Achterberg WP. Health status measured by the Clinical COPD Questionnaire (CCQ) improves following post-acute pulmonary rehabilitation in patients with advanced COPD: a prospective observational study. NPJ Prim Care Respir Med 2014;24:14007.
- Nilsen P. Making sense of implementation theories, models and frameworks. *Implement Sci* 2015;10:53.
- Damschroder LJ. Clarity out of chaos: use of theory in implementation research. Psychiatry Res 2020;283:112461.
- Wachter RM, Judson TJ, Mourad M. Reimagining specialty consultation in the digital age: the potential role of targeted automatic electronic consultations. *JAMA* 2019;322:399–400.

Copyright © 2022 by the American Thoracic Society



Coronavirus disease (COVID-19) emerged in Wuhan, China, in late 2019; hit Italy in February 2020; rampaged across Europe and North

8This article is open access and distributed under the terms of the Creative Commons Attribution Non-Commercial No Derivatives License 4.0. For commercial usage and reprints, please e-mail Diane Gern (dgern@thoracic.org).

Originally Published in Press as DOI: 10.1164/rccm.202203-0617ED on April 20, 2022

America from March 2020; and subsequently struck other continents. A pandemic was declared on March 11, 2020. The biomedical research community sprang into action in a quest to save humanity. Anything sitting on the shelf with an immunomodulatory profile could be considered. A search of www.clinicaltrials.gov on July 3, 2020, identified 1,366 registered studies, of which 279 were randomized controlled trials assessing immunomodulatory therapies (1) Thirty-nine immune pathways were targeted with 90 separate interventions. By April 2021, 2,981 interventional trials had been

registered, but only 415 had been completed; of 629 phase III trials, one-eighth had been completed (2). As of April 2022, only 200 of 866 phase III trials had been completed.

Worryingly, the biological rationale underpinning many of these interventions remains questionable. The oft-trumpeted cytokine storm was, in most patients with COVID-19, a breeze if not a puff (3). This fact was clearly identified as early as January 24, 2020, when one of the major Wuhan publications appeared online in *The Lancet* (4). Notably, two contradictory interventional strategies, inhibition and administration, were targeted at granulocyte-macrophage colonystimulating factor (GM-CSF). Lang and colleagues attempted to reconcile these conflicting approaches (5), speculating that administration could benefit during early COVID-19 disease by stabilizing alveolar macrophage and epithelial cell function, increasing severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) clearance, protecting against secondary infection, and aiding lung repair. Inhibition could be useful later, in moderate to severe disease, counteracting the proinflammatory effects of GM-CSF and myeloid cell overactivation, thereby quenching the cytokine storm. Identifying when the crossover should optimally or safely occur was not elaborated upon.

In this issue of the *Journal*, Criner and colleagues (pp. 1290–1299) report a double-blind study (BREATHE [A Study to Assess the Efficacy and Safety of Gimsilumab in Subjects With Lung Injury or Acute Respiratory Distress Syndrome Secondary to COVID-19]) assessing the impact of gimsilumab, an anti-GM-CSF monoclonal antibody, on hospitalized patients with COVID-19 pneumonia (6). The trial was impressively quick off the mark. Enrollment commenced on April 15, 2020, a mere 5 weeks after the pandemic was declared. This achievement was all the more notable, considering that they had to develop a protocol and statistical plan, undergo regulatory and ethical review, identify study sites, obtain local approvals, generate case record forms, and distribute blinded drugs. Although this pace would be unsustainable under normal circumstances, it highlights what can be accomplished when bureaucratic hurdles are removed without compromising trial integrity, quality, and safety. This represents an important lesson to be taken from the COVID-19 response, but one I fear will be lost as we regress to the status quo.

At study entry, the patients ranged from requiring low-dose supplemental oxygen to needing mechanical ventilation. Study inclusion required raised inflammatory markers with a C-reactive protein threshold ≥ 50 mg/L or ferritin $\geq 1,000$ ng/ml in the belief that this reflected hyperimmune activation that would respond positively to blocking the proinflammatory effects of GM-CSF. At least one dose of the study drug was administered to 225 patients, after which the trial was discontinued prematurely because of futility. No significant impact was seen in any predetermined outcome parameter, including the primary outcome (Day 43 mortality) or others such as time on a ventilator.

The investigators subsequently found nonelevated plasma concentrations of GM-CSF in most of their patients, a finding also noted in *The Lancet* Wuhan study (4). If the general absence of the biological target had been recognized in advance, would they have progressed with the study in the first place, been more circumspect in terms of initial ambition, or tried to first identify readily measurable surrogates that correlate with raised GM-CSF concentrations to enrich their study population? Nonetheless, it is to their huge credit

that they actually collected and analyzed blood samples. Failure to do so in the large majority of interventional COVID-19 studies means many questions remain unanswered, particularly with regard to understanding the biological response to the interventions and in identifying subsets of patients who could potentially benefit or be harmed. Counter to the prevailing philosophy of pragmatic trials, should sample biobanking not be a prerequisite, particularly when uncertainty surrounds pathophysiological mechanisms and response to treatment?

It requires a more detailed discussion for another time and place, but I still harbor doubts about the efficacy of specific immunomodulating agents in COVID-19 disease, such as when positive results in open-label studies have not been replicated by methodologically more rigorous double-blind studies (7). Why should IL-6 receptor blockade work when plasma IL-6 concentrations are rarely elevated to any significant degree (3)? Even corticosteroid therapy gets a lukewarm approval rating from a Cochrane systematic review (8). An appropriately targeted treatment could benefit specific patient subsets, avoiding futility or even harm in others. In a retrospective analysis of corticosteroid response, survival benefit was seen only in the minority of patients with COVID-19 with a baseline hyperinflammatory state (9).

Lessons either have been ignored or have not been learned from the repeated trial failures during three decades of one-size-fits-all immunomodulatory strategies for sepsis. With so many studies performed on a single disease, some positive results would be predicted by chance. To my knowledge, positive findings have not been consistently reproduced for any single therapeutic intervention in COVID-19 disease. With respect to other large anti-GM-CSF trials, lenzilumab (a GM-CSF-neutralizing monoclonal antibody) was associated with improved Day 28 survival without invasive mechanical ventilation, though the perhaps more pertinent outcome of overall mortality failed to reach significance (10% vs. 14% placebo; P = 0.24) (10). The OSCAR (Otilimab in Severe COVID-19 Related Disease) trial, published as a preprint in April 2021 (11) but still to appear in a peer-reviewed publication, randomized 806 patients to otilimab, another anti-GM-CSF monoclonal antibody, or to placebo. Again, no overall survival benefit was shown, but there was a significant reduction in predefined model-adjusted 60-day all-cause mortality in patients aged ≥70 years. The argument made here was that older patients could be predisposed to inappropriate, myeloid cell-driven hyperinflammation because of normal aging of the immune system. This prompted continuation of the study in this subset only, but a recent posting (clinicaltrials.gov/ct2/show/results/ NCT04376684) also revealed no survival benefit (all-cause mortality 42.3% vs. 43.4% placebo). A randomized, double-blind trial (NCT04447469) of the anti–GM-CSF receptor- α monoclonal antibody, mavrilimumab, enrolled 815 patients but has not yet been published. As for GM-CSF administration, several trials have been performed in patients with COVID-19 using sargramostim or molgramostim, but none have yet been reported in peer-reviewed

In summary, high-quality trials can be developed, regulated, and conducted at pace. My plea, however, is for less of the hare and more of the tortoise. We certainly do not want a ponderous tempo, especially in a novel pandemic. However, a more circumspect, stepwise, directed approach would have likely yielded greater dividends, enabling more focus on testing biologically appropriate therapies in the right patient subsets.

Editorials 1259

<u>Author disclosures</u> are available with the text of this article at www.atsjournals.org.

Mervyn Singer, M.B. B.S., M.D. Intensive Care Medicine University College London London, United Kingdom

ORCID ID: 0000-0002-1042-6350 (M.S.).

References

- Snow TAC, Singer M, Arulkumaran N. Immunomodulators in COVID-19: two sides to every coin. Am J Respir Crit Care Med 2020;202: 1460–1462
- Singer M, Kalil A. Do not just sit there, do something ... but do no harm: the worrying aspects of COVID-19 experimental interventions. *Intensive Care Med* 2021;47:896–898.
- Leisman DE, Ronner L, Pinotti R, Taylor MD, Sinha P, Calfee CS, et al. Cytokine elevation in severe and critical COVID-19: a rapid systematic review, meta-analysis, and comparison with other inflammatory syndromes. Lancet Respir Med 2020;8:1233–1244.
- Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020;395:497–506.

- Lang FM, Lee KMC, Teijaro JR, Becher B, Hamilton JA. GM-CSF-based treatments in COVID-19: reconciling opposing therapeutic approaches. *Nat Rev Immunol* 2020;20:507–514.
- Criner GJ, Lang FM, Gottlieb RL, Mathews KS, Wang TS, Rice TW, et al. Antigranulocyte—macrophage colony—stimulating factor monoclonal antibody gimsilumab for COVID-19 pneumonia: a randomized, double-blind, placebocontrolled trial. Am J Respir Crit Care Med 2022;205:1290–1299.
- Shankar-Hari M, Vale CL, Godolphin PJ, Fisher D, Higgins JPT, Spiga F, et al.; WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group. Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: a meta-analysis. JAMA 2021;326:499–518.
- Wagner C, Griesel M, Mikolajewska A, Mueller A, Nothacker M, Kley K, et al. Systemic corticosteroids for the treatment of COVID-19. Cochrane Database Syst Rev 2021;8:CD014963.
- Sinha P, Furfaro D, Cummings MJ, Abrams D, Delucchi K, Maddali MV, et al. Latent class analysis reveals COVID-19-related acute respiratory distress syndrome subgroups with differential responses to corticosteroids. Am J Respir Crit Care Med 2021;204:1274–1285.
- Temesgen Z, Burger CD, Baker J, Polk C, Libertin CR, Kelley CF, et al.; LIVE-AIR Study Group. Lenzilumab in hospitalised patients with COVID-19 pneumonia (LIVE-AIR): a phase 3, randomised, placebocontrolled trial. Lancet Respir Med 2022;10:237–246.
- Patel J, Beishuizen A, Bocca Ruiz X, Boughanmi H, Cahn A, Criner GJ, et al. A randomized trial of otilimab in severe COVID-19 pneumonia (OSCAR). medRxiv; 2021 [accessed 2022 Apr 25]. Available from: https://doi.org/10.1101/2021.04.14.21255475.

Copyright © 2022 by the American Thoracic Society



3 High Positive End-Expiratory Pressure and Lung Recruitment in Moderate to Severe Acute Respiratory Distress Syndrome Does One Size Really Fit All?

Since David Ashbaugh turned the positive end-expiratory pressure (PEEP) knob for the first time to stabilize a 12-year-old patient with acute respiratory distress syndrome (ARDS) in 1964, ARDS as well as PEEP have transitioned to behemothian entities in respiratory critical care (1).

Although PEEP was initially considered primarily an oxygenation-improving intervention, its major role in preventing ventilator-induced lung injury through alveolar recruitment, reduction of stress between heterogeneously ventilated airspaces, and minimization of cyclic distal airway closing was soon recognized. Recruitment maneuvers, consisting of a transient and pronounced elevation of transpulmonary pressure over a few seconds to multiple minutes, were proposed shortly thereafter to achieve even larger aeration of the lung. However, despite their strong theoretical foundation, neither high PEEP nor recruitment maneuvers have succeeded in improving clinical outcomes. Much to the contrary, their potential to harm has become readily apparent (2, 3).

8This article is open access and distributed under the terms of the Creative Commons Attribution Non-Commercial No Derivatives License 4.0. For commercial usage and reprints, please e-mail Diane Gern (dgern@thoracic.org).

Originally Published in Press as DOI: 10.1164/rccm.202202-0281ED on March 17, 2022

In this issue of the *Journal*, Dianti and colleagues (pp. 1300-1310) report a Bayesian network meta-analysis of 18 randomized trials in which they attempt to unravel the effects of lower and higher PEEP, as well as brief and prolonged lung recruitment maneuvers, on 28-day mortality in patients with moderate to severe ARDS ($Pa_{O_2}/FI_{O_2} \le 200 \text{ mm Hg}$) (4). Network meta-analyses allow comparison of multiple therapy combinations by merging direct and indirect evidence. Direct evidence emanates from pooling of effectively performed head-to-head treatment trials. Indirect evidence, on the other hand, is estimated by modeling "loops" of evidence. In this way, trials comparing treatments A and B are combined with trials comparing treatments B and C to estimate the effect of treatment A against that of treatment C, thus enabling exploration of previously untested hypotheses. In addition, through the Bayesian approach prior knowledge is included into Bayesian network meta-analyses, which permits estimation of the intuitive posterior probability of treatment efficacy.

In their well-performed Bayesian network meta-analysis, Dianti and colleagues show that, in the included 4,646 patients with moderate to severe ARDS, the use of higher PEEP was superior to that of lower PEEP regarding 28-day mortality, with a posterior probability of treatment efficacy of 99% and a high certainty of benefit. Similarly, the use of a brief recruitment maneuver (<60 s) coupled to higher PEEP and the titration of PEEP by means of an esophageal pressure probe were both associated with moderate